Compound ID | 2186

Update compound information

TBI-223

Class: Oxazolidinone

Spectrum of activity: Gram-positive
Details of activity: Active against Staphylococcus aureus (first report) and Mycobacterium tuberculosis
Description: Synthetic compound; may replace linezolid in BPaL regimen to treat drug-susceptible and -resistant TB
Institute where first reported: TB Alliance (New York, NY, USA) and the Institute of Materia Medica (Shanghai, People’s Republic of China)
Year first mentioned: 2019
Highest developmental phase: Phase 1 (NCT04865536)
Development status: Active (as of 2023)
Chemical structure(s):
Click here for structure editor
Molecular weight: 365.36
Iso. SMILES: COC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CC4(C3)COC4)F
InChI Key: ZNBRXLSWXJKKLJ-LBPRGKRZSA-N
Can. SMILES: COC(=O)NC[C@H]1CN(C2=CC=C(C(=C2)F)N3CC4(C3)COC4)C(=O)O1
InChI: InChI=1S/C17H20FN3O5/c1-24-15(22)19-5-12-6-21(16(23)26-12)11-2-3-14(13(18)4-11)20-7-17(8-20)9-25-10-17/h2-4,12H,5-10H2,1H3,(H,19,22)/t12-/m0/s1
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/126494519
Guide to Pharmacology: TBI-223
Citations:
  • https://journals.asm.org/doi/full/10.1128/spectrum.02451-21?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org
  • https://journals.asm.org/doi/10.1128/aac.00035-23

    • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.